Overview

The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies.

The main purposes of the study are the following:

• Identify the demographic factors related to the onset of cardiotoxicity produced by anticancer drugs.
• Identify any subgroups more likely to develop distant major adverse cardiovascular events (MACE).
• Evaluate the usefulness of clinical, biohumoral and echocardiographic parameters for early diagnosis of cardiotoxicity.

Participants will be monitored during the anticancer treatment via clinical, laboratory and instrumental evaluation according to the recommendation of the current guidelines on Cardio-Oncology (European Society of Cardiology, 2022). Initial follow-up will be 2 years.

Eligibility

Inclusion Criteria:

• Patients over the age of 18 at the time of evaluation
• Patients treated with potentially cardiotoxic anticancer drugs
• Patients for which complete clinical, electrocardiographic and echocardiographic data are available at first evaluation and at least at one follow-up visit.

Exclusion Criteria:

• Patients under the age of 18 at the time of evaluation
• Patients whose documentation of the first visit is not available
• Patients for whom it is not possible to obtain follow-up information through a medical visit or by telephone
• Patient with poor acoustic window for echocardiographic examination.
• Refusal of informed consent to participate in the study.